Back to top
more

Shockwave Medical Inc. (SWAV)

(Delayed Data from NSDQ)

$43.43 USD

43.43
437,633

+2.29 (5.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $43.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ensign Group (ENSG) Rises 30% in 6 Months: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for improvement on growing revenues derived from catering to patients under Medicaid and Medicare programs. Solid cash flows are other tailwinds.

Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on strong growth in the base business.

Abbott's (ABT) FreeStyle Libre 3 Integrates With AID System

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre 3 integration with mylife Loop solutions will help build a smart, automated process to deliver insulin based on real-time glucose data.

Walgreens Boots (WBA) Gains From Digital Sales Amid Cost Woes

by Zacks Equity Research

Within the U.S. Healthcare segment, Walgreens Boots (WBA) is optimistic about the acquisition of CareCentrix.

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX), led by new strategic investments and the robust performance of the WATCHMAN device.

Thermo Fisher's (TMO) Monkeypox Test Receives FDA EUA

by Zacks Equity Research

Thermo Fisher's (TMO) monkeypox test kit is a PCR test intended to spot non-variola Orthopoxviruses, including the monkeypox virus.

Here's Why You Should Retain NextGen (NXGN) Stock for Now

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

McKesson (MCK) Announces Availability of FDA-Approved Drug

by Zacks Equity Research

The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business and product launches.

Abbott's (ABT) Eterna SCS System Receives FDA's Approval

by Zacks Equity Research

Abbott's (ABT) Eterna SCS technology shows 23% more pain reduction compared with traditional waveform technology approaches.

Edwards Lifesciences (EW) Rides on Innovation Amid Rising Costs

by Zacks Equity Research

Edwards Lifesciences (EW) expects to report underlying sales growth in the mid-single-digit range for 2022, banking on market growth and the adoption of premium technologies.

QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada

by Zacks Equity Research

QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.

Charles River (CRL) Benefits From Price Rise Amid FX Woe

by Zacks Equity Research

Charles River's (CRL) RMS growth prospects are high, courtesy of accelerating growth for research model services and research models.

QuidelOrtho's (QDEL) Latest JV to Boost Footprint in China

by Zacks Equity Research

QuidelOrtho's (QDEL) new JV will likely translate into a faster time-to-market and a more compelling menu for VITROS assays in support of its growth strategy in China and beyond.

Ensign Group (ENSG) Unveils Dividend Hike to Reward Shareholders

by Zacks Equity Research

Ensign Group's (ENSG) latest dividend hike reflects strong financial standing and intensified focus in the tactical deployment of capital.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE), led by strong segmental growth and the Cantel Medical acquisition.

Henry Schein (HSIC) Expands Dental Offerings With New Pact

by Zacks Equity Research

Henry Schein's (HSIC) latest deal expands its offering in several fast-growing product segments, including clinical software and oral surgery and orthodontic products.

Tandem (TNDM) to Expand Global Insulin Pump Base With New Buy

by Zacks Equity Research

The AMF Medical acquisition will help Tandem (TNDM) advance with its sustainability objectives by offering an additional pump that minimizes electronic and battery waste generation.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors are optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Stryker's (SYK) Citrefix to Boost Foot and Ankle Surgeries

by Zacks Equity Research

Stryker's (SYK) newly-launched Citrefix will help customers avoid chronic inflammation using Citregen. Its pull-out strength is greatly increased compared to other suture anchors.

STERIS (STE) Gains on New Orders, FX Impact Dents Growth

by Zacks Equity Research

STERIS (STE) is on track to achieve its stated goal of approximately $50 million of cost synergies in fiscal 2023.

Medtronic (MDT) Enrolls 1st Patient Trial for Hugo RAS System

by Zacks Equity Research

Medtronic's Hugo RAS system is designed to be used in Expand URO U.S. clinical trial study for urologic surgical procedures.